TOGETHER FOR CHANGE GENOMICS AND EQUITY INITIATIVE LAUNCHED BY A COALITION OF MEHARRY MEDICAL COLLEGE, REGENERON GENETICS CENTER, ASTRAZENECA, NOVO NORDISK, AND ROCHE TO IMPROVE HEALTH OUTCOMES FOR PEOPLE OF AFRICAN ANCESTRY

TOGETHER FOR CHANGE GENOMICS AND EQUITY INITIATIVE LAUNCHED BY A COALITION OF MEHARRY MEDICAL COLLEGE, REGENERON GENETICS CENTER, ASTRAZENECA, NOVO NORDISK, AND ROCHE TO IMPROVE HEALTH OUTCOMES FOR PEOPLE OF…

Read MoreTOGETHER FOR CHANGE GENOMICS AND EQUITY INITIATIVE LAUNCHED BY A COALITION OF MEHARRY MEDICAL COLLEGE, REGENERON GENETICS CENTER, ASTRAZENECA, NOVO NORDISK, AND ROCHE TO IMPROVE HEALTH OUTCOMES FOR PEOPLE OF AFRICAN ANCESTRY

European Commission Approves ADCETRIS for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD Takeda (TSE:4502/NYSE:TAK) today announced that the European…

Read MoreEuropean Commission Approves ADCETRIS for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

R&D Postdoctoral Challenge is a ground-breaking initiative fostering collaboration, innovation and global diversity

R&D Postdoctoral Challenge is a ground-breaking initiative fostering collaboration, innovation and global diversity AstraZeneca announced today eight winners of the 2023 R&D Postdoctoral Challenge and agreed to fund their postdoctoral positions at…

Read MoreR&D Postdoctoral Challenge is a ground-breaking initiative fostering collaboration, innovation and global diversity

Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease

Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease Merck (NYSE: MRK), known…

Read MoreMerck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease

Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer

Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC) Merck (NYSE: MRK), known as…

Read MoreMerck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer